Belyhun Yeshambel, Maier Melanie, Mulu Andargachew, Diro Ermias, Liebert Uwe Gerd
Institute of Virology, Faculty of Medicine, Leipzig University, Leipzig, Germany.
School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
BMC Infect Dis. 2016 Dec 19;16(1):761. doi: 10.1186/s12879-016-2090-1.
The existing seroepidemiological data on viral hepatitis in Ethiopia showed a wide variation in prevalence pattern and the clinical and public health burden have been underestimated. The aim of this systematic review and meta-analysis was to provide a clear and comprehensive estimation of viral hepatitis epidemiology and the potential clinical burdens in Ethiopia.
A comprehensive literature search was carried out from five decades (1968-2015) published studies from biomedical databases; PubMed, Google scholar, Medline and Web of Science.
The overall pooled prevalence of hepatitis B virus (HBV) was 7.4% (95%CI: 6.5-8.4). The pooled prevalence among subgroups showed 5.2% (95%CI: 3.7-7.4) in human immunodeficiency virus (HIV) infected individuals, 8.0% (95%CI: 5.9-10.7) in community based studies, 8.4% (95%CI: 5.4-12.7) in blood donors, 11.0% (95%CI: 7.5-15.9) in immigrants and 6.9% (95%CI: 5.6-8.5) in other groups. Among study parameters considered during meta-regression analysis, only study years were associated with a decreasing HBV prevalence rate over time. The overall pooled prevalence of anti-hepatitis C virus antibody (anti-HCV) was 3.1% (95%CI: 2.2-4.4). Unlike HBV, the anti-HCV prevalence in HIV infected individuals was higher (5.5%, 95%CI: 3.8-7.8%, p = 0.01) than the prevalence observed in the other subgroup of study population. Although relatively few data were available, hepatitis virus A (HAV), D (HDV) and E (HEV) were also circulated in Ethiopia.
This review indicates that all types of viral hepatitis origins are endemic in Ethiopia. Adapting a recommended diagnostic and treatment algorithm of viral hepatitis in the routine healthcare systems and implementing prevention and control policies in the general population needs an urgent attention.
埃塞俄比亚现有的病毒性肝炎血清流行病学数据显示,患病率模式差异很大,临床和公共卫生负担被低估。本系统评价和荟萃分析的目的是对埃塞俄比亚病毒性肝炎的流行病学和潜在临床负担进行清晰全面的评估。
从生物医学数据库(PubMed、谷歌学术、Medline和科学网)发表的五十年(1968 - 2015年)研究中进行全面的文献检索。
乙型肝炎病毒(HBV)的总体合并患病率为7.4%(95%置信区间:6.5 - 8.4)。亚组中的合并患病率显示,人类免疫缺陷病毒(HIV)感染者为5.2%(95%置信区间:3.7 - 7.4),社区研究为8.0%(95%置信区间:5.9 - 10.7),献血者为8.4%(95%置信区间:5.4 - 12.7),移民为11.0%(95%置信区间:7.5 - 15.9),其他组为6.9%(95%置信区间:5.6 - 8.5)。在荟萃回归分析中考虑的研究参数中,只有研究年份与HBV患病率随时间下降有关。抗丙型肝炎病毒抗体(抗-HCV)的总体合并患病率为3.1%(95%置信区间:2.2 - 4.4)。与HBV不同,HIV感染者中的抗-HCV患病率(5.5%,95%置信区间:3.8 - 7.8%,p = 0.01)高于研究人群其他亚组中的患病率。虽然可用数据相对较少,但甲型肝炎病毒(HAV)、丁型肝炎病毒(HDV)和戊型肝炎病毒(HEV)在埃塞俄比亚也有传播。
本综述表明,所有类型的病毒性肝炎在埃塞俄比亚均为地方病。在常规医疗系统中采用推荐的病毒性肝炎诊断和治疗算法,并在普通人群中实施预防和控制政策需要紧急关注。